Celeris Therapeutics

CelerisTx, founded in 2020, is dedicated to filling the knowledge gap in the rational design of these compounds. The company's Celeris One platform is a closed-loop discovery engine capable of predicting biomolecular interactions. It generates new chemical entities that meet the success criteria for relevant degraders and extends this knowledge to synthesis and biochemical validation. The application of this discovery engine is expected to streamline the discovery of potent degraders while enhancing the productivity of upstream R&D. The company’s mission is to control pathogenic proteins for patients with significant unmet needs by bringing multiple first-in-class small molecule drugs to market by 2035.